Expression of heparanase in soft tissue sarcomas of adults

Journal of Experimental & Clinical Cancer Research

Gil Bar-Sela²  Israel Vlodavsky¹  Ofer Ben-Itzhak³  Inna Naroditzky³  Neta Ilan¹  Olga Kazarin² 

[1] Cancer and Vascular Biology Research Center, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel;Division of Oncology, Rambam Health Care Campus, 8 Ha’Aliyah Street, Haifa 35254, Israel;Pathology Institute, Rambam Health Care Campus, Haifa, Israel

关键词: Soft tissue;    Sarcoma;    Recurrence;    Heparanase;    Expression;   

Others  :  802693
DOI  :  10.1186/1756-9966-33-39

 received in 2014-03-27, accepted in 2014-04-30,  发布年份 2014

【 摘 要 】

Background

Heparanase is an endo-β-D-glucuronidase that cleaves heparan sulfate chains of proteoglycans, resulting in the disassembly of the extracellular matrix. Heparanase has a central role in the development of various tumors, and its expression has been associated with increased tumor growth, angiogenesis and metastasis, but there is insufficient information about the function of heparanase in sarcomas.

Study aims

1) To evaluate heparanase levels in adult soft tissue sarcomas (STS); 2) To examine the correlation between heparanase levels and pathological and clinical parameters and treatment outcome.

Methods

Pathological specimens of primary or metastatic STS were subjected to immunohistochemical analysis applying an anti-heparanase antibody. The clinical and the pathological data, together with the data of heparanase levels, were evaluated in a logistic regression model for tumor recurrence and survival.

Results

One hundred and one samples were examined, 55 from primary tumors and 46 from metastatic sites. A high expression of heparanase was observed in 29 (52.7%) and 22 specimens (47.8%), respectively. There was no statistically significant difference between heparanase expressions in the primary vs. metastatic sites of tumors. Moreover, no correlation was observed between heparanase staining and tumor aggressiveness, tumor recurrence or patient survival in various groups of patients.

Conclusion

Expression of heparanase was observed in 50% of the STS, in various histological subtypes. A larger study with homogenous groups of specific sub-types of STS or stages of disease is required to validate over-expression of heparanase as a marker of disease aggressiveness.

【 授权许可】

   
2014 Kazarin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I: Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 2010, 277:3890-3903.
• [2]Ilan N, Elkin M, Vlodavsky I: Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006, 38:2018-2039.
• [3]Parish CR, Freeman C, Hulett MD: Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001, 1471:M99-M108.
• [4]Vlodavsky I, Friedmann Y: Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001, 108:341-347.
• [5]Fux L, Ilan N, Sanderson RD, Vlodavsky I: Heparanase: busy at the cell surface. Trends Biochem Sci 2009, 34:511-519.
• [6]Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I: The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev 2011, 30:253-268.
• [7]Vreys V, David G: Mammalian heparanase: what is the message? J Cell Mol Med 2007, 11:427-452.
• [8]Vlodavsky I, Beckhove P, Lerner I, Pisano C, Meirovitz A, Ilan N, Elkin M: Significance of heparanase in cancer and inflammation. Cancer Microenviron 2012, 5:115-132.
• [9]Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, Brandt R, Ferro V, Bytheway I: PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer 2011, 104:635-642.
• [10]Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M, Zunino F, Vlodavsky I, Sanderson RD, Yang Y: SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 2011, 17:1382-1393.
• [11]Barash U, Cohen-Kaplan V, Arvatz G, Gingis-Velitski S, Levy-Adam F, Nativ O, Shemesh R, Ayalon-Sofer M, Ilan N, Vlodavsky I: A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J 2010, 24:1239-1248.
• [12]Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, Peretz T, Vlodavsky I, Abramovitch R: Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 2006, 118:1609-1617.
• [13]Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N: Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006, 66:1455-1463.
• [14]Lerner I, Baraz L, Pikarsky E, Meirovitz A, Edovitsky E, Peretz T, Vlodavsky I, Elkin M: Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res 2008, 14:668-676.
• [15]Basche M, Gustafson D, Holden S, O’Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG: Phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 2006, 12:5471-5480.
• [16]Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, Tortoreto M, Cassinelli G, Lanzi C, Pisano C, Ilan N, Vlodavsky I, Zunino F: Pre clinical and clinical significance of heparanase in Ewing’s sarcoma. J Cell Mol Med 2011, 15:1857-1864.
• [17]Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S: Multicentre phase I\II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with castrate-resistant prostate cancer. Ann Oncol 2010, 21:1302-1307.
• [18]Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, Walpole ET, Haydon AM, Creese BR, Roberts KL, Zalcberg JR, Gonzalez R: A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 2008, 26:89-94.
• [19]Cassinelli G, Lanzi C, Tortoreto M, Cominetti C, Petrangolini G, Favini E, Zaffaroni N, Pisano C, Penco S, Vlodavsky I, Zunino F: Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol 2013, 10:1424-1432.
• [20]Singer S, Maki RG, O’Sullivan B: Soft tissue sarcoma. In DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th edition. Edited by DeVita VT, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA. Philadelphia PA, USA: Lippincott Williams & Wilkins; 2011:Chapter 115.
• [21]Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, Flugelman MY, Vlodavsky I, Ilan N: Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004, 117:2249-2258.
• [22]Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I, Ilan N: Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 2008, 68:10077-10085.
• [23]Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, Doweck I: Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 2008, 123:2566-2573.
• [24]Masola V, Maran C, Tassone E, Zin A, Rosolen A, Onisto M: Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion. BMC Cancer 2009, 9:304. BioMed Central Full Text
• [25]Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I, Pappo O: Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol 2000, 157:1167-1175.
• [26]Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I, Zimmermann A, Buchler MW: Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001, 61:4655-4659.
• [27]Maxhimer JB, Quiros RM, Stewart R, Dowlatshahi K, Gattuso P, Fan M, Prinz RA, Xu X: Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery 2002, 132:326-333.
• [28]Wang LL, Yustein J, Louis C, Russell HV, Pappo AS, Paulino A, Nuchtern JG, Chintagumpala M: Solid Tumors of Childhood. In DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th edition. Edited by DeVita VT, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA. Philadelphia PA, USA: Lippincott Williams & Wilkins; 2011:Chapter 123.